Gwella triniaeth ffibrosis systig gyda gwymon y môr
Yn datblygu triniaethau newydd i herio afiechyd ysgyfaint bacteriol sy’n bygwth bywyd ac yn gwrthsefyll gwrthfiotigau.
Cystic fibrosis is an incurable genetic condition which causes the organs, especially the lungs and digestive system, to become clogged with thick sticky mucus. Bacterial colonisation of patients’ lungs eventually leads to chronic infection.
The situation is made worse by the rising numbers of bacteria that don’t respond to antibiotics, making these chronic infections difficult to treat.
The Advanced Therapies Group (Professor David Thomas, Dr Katja Hill, Dr Lydia Powell, Dr Manon Pritchard and Dr Elaine Ferguson) are working to develop a new treatment from seaweed for this debilitating disease and other chronic infections.
Developing a drug
For the last nine years they have worked in collaboration with the Norwegian company AlgiPharma AS. Together they have developed an inhalation therapy to help remove the thick stagnant mucus and bacterial biofilms that characterise chronic lung disease in cystic fibrosis patients. They are now working with scientists and clinicians around the world to test and develop the drug, called OligoG, for clinical use.
Using specialised microscopy techniques and microbiological assays, the group have shown that OligoG is able to impair and disrupt bacterial biofilm growth in the laboratory. They have also shown that it can make antibiotics more effective against resistant bacteria. OligoG therefore has exciting potential that could prolong the life of cystic fibrosis patients. OligoG, the drug candidate for cystic fibrosis now has Orphan Drug designation from both the European Medicines Agency and the US Federal Drugs Administration.
Improving lung clearance in cystic fibrosis patients
Chronic infection and mucus over-production in cystic fibrosis favours the accumulation of bacteria in the lungs, restricting the access of antibiotics and hampering effective treatment. The agent OligoG effectively breaks down this mucus "barrier" allowing lung clearance, and enhances treatment of antibiotic-resistant bacteria in these life-limiting lung infections.
While the research is continuing in the laboratory, Phase I and Phase II clinical trials have established that OligoG is safe and well tolerated in cystic fibrosis patients. Two Phase IIb clinical trials are also nearing completion in cystic fibrosis patients, with patients recruited across multiple locations in several European countries.
Yr Athro Dave W Thomas
Cyfarwyddwr y Rhaglen Mewnblaniadau Deintyddol, Cyfarwyddwr Rhaglen Hyfforddiant Academaidd Integredig Cymru mewn Deintyddiaeth, Ysgol Deintyddiaeth, Arweinydd Arloesedd Sefydliadau Ymchwil y Brifysgol
- +44 (0)29 207 44873
Dr Katja Hill
Cymrawd Ymchwil Ôl-Ddoethurol
- +44 (0)29 225 10661